Objective: We conducted a study on the functional characteristics of mitochondria in an oxyphilic thyroid tumor cell line, which may provide useful clues about Hürthle cell tumors carcinogenesis.
Design: The functional study on thyroid tumors with cell oxyphilia (Hürthle cell tumors), characterized by mitochondrial hyperplasia, was carried out in XTC.UC1, and B-CPAP, an oxyphilic and nonoxyphilic thyroid tumor cell line, respectively.
Main Outcome: XTC.UC1 cell line showed higher activity of mitochondrial respiratory complexes I and II and decreased activity of complex III. The increased activity of complex I was not matched by increased expression of complex I subunits. The XTC.UC1 cells relied mostly on oxidative phosphorylation for energy conservation, although their mitochondrial energetic function was less efficient when related to mitochondrial content of the cells. Finally, the oxyphilic cell line produced significantly higher amounts of reactive oxygen species (ROS) in comparison with B-CPAP cell line.
Conclusion: The involvement of ROS in mitochondrial biogenesis and proliferation as well as in carcinogenesis and apoptosis indicate that differences in activity of respiratory chain components and their unbalance may be responsible for development of morphological and functional changes observed in thyroid tumors with cell oxyphilia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/thy.2006.16.325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The autophagy lysosomal pathway (ALP) and the ubiquitin-proteasome system (UPS) are key proteostasis mechanisms in cells, which are dysfunctional in AD and linked to protein aggregation and neuronal death. Autophagy is over activated in Alzheimer's disease brain whereas UPS is severely impaired. Activating autophagy has received most attention, however recent evidence suggests that UPS can clear aggregate proteins and a potential therapeutic target for AD and protein misfolding diseases.
View Article and Find Full Text PDFBackground: There is an urgent need for new therapeutic and diagnostic targets for Alzheimer's disease (AD). Dementia afflicts roughly 55 million individuals worldwide, and the prevalence is increasing with longer lifespans and the absence of preventive therapies. Given the demonstrated heterogeneity of Alzheimer's disease in biological and genetic components, it is critical to identify new therapeutic approaches.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is the most common cause of dementia worldwide. It is characterized by dysfunction in the U1 small nuclear ribonucleoproteins (snRNPs) complex, which may precede TAU aggregation, enhancing premature polyadenylation, spliceosome dysfunction, and causing cell cycle reentry and death. Thus, we evaluated the effects of a synthetic single-stranded cDNA, called APT20TTMG, in induced pluripotent stem cells (iPSC) derived neurons from healthy and AD donors and in the Senescence Accelerated Mouse-Prone 8 (SAMP8) model.
View Article and Find Full Text PDFBackground: Immunotherapy of Alzheimer's disease (AD) is a promising approach to reducing the accumulation of beta-amyloid, a critical event in the onset of the disease. Targeting the group II metabotropic glutamate receptors, mGluR2 and mGluR3, could be important in controlling Aβ production, although their respective contribution remains unclear due to the lack of selective tools.
Method: 5xFAD mice were chronically treated by a brain penetrant camelid single domain antibody (VHH or nanobody) that is an activator of mGluR2.
Drug Development.
Alzheimers Dement
December 2024
Columbia University Irving Medical Center, New York, NY, USA.
Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!